Trial · NCT05951205
Registered outcomes32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 32
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Participants with an Average Fetal Hemoglobin (HbF) Greater Than or Equal To (>=) 20 percent (%) on or After 6 Months | From 60 Days after Last Red Blood Cell (RBC) transfusion up to 24 Months after exa-cel infusion | |
| Secondary | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | From Signing of Informed Consent up to 24 Months After exa-cel Infusion | |
| Secondary | Proportion of Participants With Neutrophil Engraftment (First day of 3 Consecutive Measurements of Absolute Neutrophil Count (ANC) >=500 per Microliter [mcgL] on 3 Different Days) | Within 42 Days After exa-cel Infusion | |
| Secondary | Time to Neutrophil Engraftment | Up to 24 months After exa-cel Infusion | |
| Secondary | Time to Platelet Engraftment | Up to 24 months After exa-cel Infusion | |
| Secondary | Incidence of Transplant-Related Mortality (TRM) | Up to 100 Days After exa-cel Infusion | |
| Secondary | Incidence of Transplant-Related Mortality (TRM) | Within 12 Months After exa-cel Infusion | |
| Secondary | Incidence of All-cause Mortality | From Signing of Informed Consent up to 24 Months After exa-cel Infusion | |
| Secondary | Proportion of Participants With No Severe Vaso-Occlusive Crises (VOCs) for At least 12 Months (VF12) | From 60 Days after Last RBC transfusion up to 24 Months After exa-cel Infusion | |
| Secondary | Proportion of Participants Free from Inpatient Hospitalization For Severe VOCs Sustained for At least 12 Months (HF12) | From 60 Days after Last RBC transfusion up to 24 Months After exa-cel Infusion | |
| Secondary | Relative Reduction in Annualized Rate of Severe VOCs | From Baseline up to 24 Months After exa-cel Infusion | |
| Secondary | Duration of Severe VOC Free in Participants who Have Achieved VF12 | From 60 Days after Last RBC transfusion up to 24 Months After exa-cel Infusion | |
| Secondary | Relative Reduction in Rate of Inpatient Hospitalizations for Severe VOCs | From Baseline up to 24 Months After exa-cel Infusion | |
| Secondary | Relative Reduction in Annualized Duration of Hospitalization for Severe VOCs | From Baseline up to 24 Months After exa-cel Infusion | |
| Secondary | Proportion of Participants With Sustained HbF >= 20 % for At least 3, 6, or 12 months | From 60 Days after Last RBC transfusion up to 24 Months After exa-cel Infusion | |
| Secondary | Relative Reduction in Annualized Volume of RBC Transfusions | From Baseline Up To 24 Months After exa-cel Infusion | |
| Secondary | HbF Concentration Over Time | Up To 24 Months After exa-cel Infusion | |
| Secondary | Total Hemoglobin (Hb) Concentration Over Time | Up To 24 Months After exa-cel Infusion | |
| Secondary | Change In Reticulocyte Count Over Time | From Baseline Up To 24 Months After exa-cel Infusion | |
| Secondary | Change in Indirect Bilirubin Over Time | From Baseline Up To 24 Months After exa-cel Infusion |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05951205/registered